Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled

Americas still the biggest region by sales – SPIRIVA®, MICARDIS® and COMBIVENT®
The majority of Boehringer Ingelheim's net sales are still made in the Americas Region. In 2010, it generated EUR 5.7 billion (2009: EUR 6.3 billion), or 46 percent of total net sales. Though this means a decline of 8.5 percent, due to the special situation with patent expiries in the USA, the business showed gratifying development after adjustment for the extraordinary components. Established products, such as SPIRIVA®, MICARDIS® and COMBIVENT®, showed distinct growth and were thus able to partially offset the sales losses. SPIRIVA®, a medicine for the treatment of chronic obstructive pulmonary disease (COPD) remains Boehringer Ingelheim's biggest product in turnover terms. In 2010, it achieved net sales of EUR 2,863 million, thereby growing by 19.1 percent against the previous year. MICARDIS®, for the treatment of high blood pressure, increased net sales by 11.6 percent to almost EUR 1,555 million. The product COMBIVENT®, approved for COPD and bronchial asthma, climbed 11.2 percent to EUR 727 million. In Europe and the Asia, Australasia, Africa Region (AAA), Boehringer Ingelheim increased net sales. The AAA Region showed itself to be the most dynamic market, with net sales rising by 11.6 percent. In the meantime, this increasingly important region, with net sales of EUR 2.8 billion (2009: EUR 2.5 billion), accounts for 22 percent of total net sales.